{"id":"imojev","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IMOJEV contains a weakened strain of Japanese encephalitis virus that replicates in vaccinated individuals without causing disease, thereby priming both cellular and humoral immune responses. This allows the immune system to recognize and neutralize wild-type Japanese encephalitis virus upon natural exposure. The vaccine is designed to provide long-term protection against Japanese encephalitis, a mosquito-borne viral disease prevalent in Asia.","oneSentence":"IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:43.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in endemic regions"}]},"trialDetails":[{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT03920111","phase":"NA","title":"Flavivirus Cross-priming Potential of IMOJEV","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2021-04-16","conditions":"Japanese Encephalitis","enrollment":19},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":"Infectious Disease, Yellow Fever, Japanese Encephalitis","enrollment":70},{"nctId":"NCT02933710","phase":"","title":"Postmarketing Surveillance Study for IMOJEV® in Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Japanese Encephalitis","enrollment":50},{"nctId":"NCT01190228","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08-25","conditions":"Japanese Encephalitis, Varicella","enrollment":454},{"nctId":"NCT02492165","phase":"PHASE3","title":"Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-06","conditions":"Japanese Encephalitis","enrollment":250},{"nctId":"NCT01900444","phase":"PHASE3","title":"Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-07-11","conditions":"Japanese Encephalitis","enrollment":119},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":"Encephalitis","enrollment":50},{"nctId":"NCT01981967","phase":"PHASE4","title":"Post-licensure Safety Study of IMOJEV® in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-11","conditions":"Japanese Encephalitis","enrollment":10000},{"nctId":"NCT01396512","phase":"PHASE3","title":"Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07","conditions":"Japanese Encephalitis, Japanese Encephalitis Virus Disease","enrollment":274},{"nctId":"NCT01954810","phase":"PHASE4","title":"Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2013-10","conditions":"Japanese Encephalitis","enrollment":88}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ANURIA"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":1,"reaction":"LACTIC ACIDOSIS"},{"count":1,"reaction":"NEPHROTIC SYNDROME"},{"count":1,"reaction":"OLIGURIA"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Japanese Encephalitis Chimeric Virus Vaccine","JE-YF17D vaccine"],"phase":"phase_3","status":"active","brandName":"IMOJEV","genericName":"IMOJEV","companyName":"SK Bioscience Co., Ltd.","companyId":"sk-bioscience-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection. Used for Prevention of Japanese encephalitis in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}